RUBY · Rubius Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue | $0 | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $96.41M | $141.59M | $116.11M | $112.42M | $8.40M |
| SG&A | $30.84M | $53.03M | $50.34M | $57.18M | $2.45M |
| Total Operating Expenses | $178.45M | $194.62M | $166.45M | $169.60M | $10.85M |
| D&A | $6.25M | $7.72M | $5.69M | $3.00M | $118.0K |
| Operating Income | ($178.45M) | ($194.62M) | ($166.45M) | ($169.60M) | ($10.85M) |
| Interest Expense | $3.86M | $6.43M | $4.18M | $2.59M | $149.0K |
| Income Tax | - | - | - | - | - |
| Net Income | ($179.67M) | ($196.55M) | ($167.73M) | ($163.46M) | ($11.02M) |
| EPS - Basic | ($2.08) | - | - | - | - |
| EPS - Diluted | ($2.08) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | $14.87M | $225.85M | $91.17M | $91.90M | $307.06M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $1.23M | $11.57M | $5.48M | $7.18M | $7.89M |
| Current Assets | $20.20M | $229.82M | $181.51M | $289.27M | $414.41M |
| Total Assets | $23.07M | $318.02M | $277.79M | $394.84M | $479.11M |
| Current Liabilities | $7.94M | $34.66M | $27.84M | $33.76M | $20.00M |
| Long-term Debt | $0 | $76.15M | $74.94M | $49.60M | $24.35M |
| Total Liabilities | $7.94M | $139.24M | $136.23M | $120.63M | $86.10M |
| Stockholders' Equity | $15.13M | $178.78M | $141.56M | ($149.28M) | ($5.56M) |
| Retained Earnings | ($856.68M) | ($677.02M) | ($480.47M) | ($60.89M) | ($150.08M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($150.14M) | ($145.12M) | ($127.65M) | ($110.44M) | ($9.50M) |
| Investing Cash Flow | $12.94M | $81.35M | $100.43M | ($132.63M) | ($443.0K) |
| Financing Cash Flow | ($75.47M) | $198.45M | $26.48M | $27.29M | $15.42M |
| CapEx | $5.30M | $3.65M | $5.50M | $40.66M | $443.0K |
| Free Cash Flow | ($155.45M) | ($148.77M) | ($133.15M) | ($151.10M) | ($9.95M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.87 | 0.76 | 0.79 | 0.92 | 0.90 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -778.8% | -61.8% | -60.4% | -41.4% | -2.3% |
| Return on equity | -1187.4% | -109.9% | -118.5% | 109.5% | 198.1% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 2.54 | 6.63 | 6.52 | 8.57 | 20.72 |
| Quick ratio | 2.54 | 6.63 | 6.52 | 8.57 | 20.72 |
| Cash ratio | 1.87 | 6.52 | 3.27 | 2.72 | 15.35 |
| Leverage | |||||
| Debt / Equity | 0.00 | 0.43 | 0.53 | -0.33 | -4.38 |
| Debt / Assets | 0.00 | 0.24 | 0.27 | 0.13 | 0.05 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -46.2x | -30.2x | -39.8x | -65.5x | -72.8x |
| Equity multiplier | 1.52 | 1.78 | 1.96 | -2.64 | -86.14 |
| Liabilities / Assets | 0.34 | 0.44 | 0.49 | 0.31 | 0.18 |
| Efficiency | |||||
| Asset turnover | 0.00 | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 8.3% | -16.9% | 1.9% | -1462.9% | - |
| Net income growth (YoY) | 8.6% | -17.2% | -2.6% | -1383.8% | - |
| EPS growth (YoY) | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -4.5% | -11.7% | 11.9% | -1419.4% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -91.5% | 26.3% | - | -2584.0% | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-54.30
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Rubius Therapeutics against the 5 most active filers in the same SIC group.